 | • レポートコード：MRC2304L022 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、255ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に1,640.1億ドルであった世界のがん診断市場規模が、2022年に1,781.9億ドルへと拡大し、その後CAGR 8.82％で成長して2027年までに2,723.6億ドルに達すると予測しています。当書は、がん診断の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、診断タイプ別（生検＆細胞診検査、画像診断検査、腫瘍バイオマーカー）分析、疾患別（血液がん、乳がん、子宮頸がん、大腸がん、腎がん）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Abbott Laboratories、Agilent Technologies Inc.、Becton Dickinson & Company、F. Hoffmann-La Roche Ltd、GE Healthcare、Hologic Inc.、Illumina Inc.、Philips Healthcare、Qiagen NV、Siemens Healthcare GmbH、Thermo Fisher Scientific Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のがん診断市場規模：診断タイプ別 - 生検＆細胞診検査の市場規模 - 画像診断検査の市場規模 - 腫瘍バイオマーカーの市場規模 ・世界のがん診断市場規模：疾患別 - 血液がんにおける市場規模 - 乳がんにおける市場規模 - 子宮頸がんにおける市場規模 - 大腸がんにおける市場規模 - 腎がんにおける市場規模 ・世界のがん診断市場規模：地域別 - 南北アメリカのがん診断市場規模 アメリカのがん診断市場規模 カナダのがん診断市場規模 ブラジルのがん診断市場規模 ... - アジア太平洋のがん診断市場規模 日本のがん診断市場規模 中国のがん診断市場規模 インドのがん診断市場規模 韓国のがん診断市場規模 台湾のがん診断市場規模 ... - ヨーロッパ/中東/アフリカのがん診断市場規模 イギリスのがん診断市場規模 ドイツのがん診断市場規模 フランスのがん診断市場規模 ロシアのがん診断市場規模 ... - その他地域のがん診断市場規模 ・競争状況 ・企業情報 |
The Global Cancer Diagnostics Market size was estimated at USD 164.01 billion in 2021 and expected to reach USD 178.19 billion in 2022, and is projected to grow at a CAGR 8.82% to reach USD 272.36 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Diagnostic Type, the market was studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.
Based on Indication, the market was studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market, including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising of aging population and rising prevalence of cancer
5.1.1.2. Increasing government initiatives for funding and awareness about cancer
5.1.1.3. Evolution of artificial intelligence and the imminent health
5.1.2. Restraints
5.1.2.1. High cost of diagnostic imaging systems
5.1.2.2. Limited skilled and trained professionals
5.1.3. Opportunities
5.1.3.1. Emerging nanotechnology in cancer diagnosis
5.1.3.2. Rise in the amalgamation strategies by the market players in the cancer diagnostics
5.1.3.3. Growing medical tourism in emerging economies
5.1.4. Challenges
5.1.4.1. Inadequate access to cancer detection and high treatment costs in lower income countries
5.1.4.2. Radiation risk from medical imaging for cancer
5.2. Cumulative Impact of COVID-19
6. Cancer Diagnostics Market, by Diagnostic Type
6.1. Introduction
6.2. Biopsy and Cytology Test
6.3. Diagnostic Imaging Test
6.4. Tumor Biomarkers
7. Cancer Diagnostics Market, by Indication
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Ovarian Cancer
7.10. Pancreatic Cancer
7.11. Prostate Cancer
7.12. Skin Cancer
8. Americas Cancer Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cancer Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cancer Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Agilent Technologies Inc.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Becton Dickinson & Company
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. GE Healthcare
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Hologic Inc.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Illumina Inc.
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Philips Healthcare
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Qiagen NV
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Siemens Healthcare GmbH
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Thermo Fisher Scientific Inc.
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing